First National Trust Co Reduces Stake in Kenvue Inc. $KVUE

First National Trust Co decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 68.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,417 shares of the company’s stock after selling 39,159 shares during the quarter. First National Trust Co’s holdings in Kenvue were worth $299,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Cornerstone Planning Group LLC raised its holdings in Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares in the last quarter. NBT Bank N A NY grew its position in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after buying an additional 1,006 shares during the last quarter. Salomon & Ludwin LLC acquired a new stake in Kenvue during the 3rd quarter worth $25,000. Golden State Wealth Management LLC lifted its position in Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares during the last quarter. Finally, Trust Co. of Vermont boosted its stake in Kenvue by 50.9% in the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 1.0%

Shares of NYSE:KVUE opened at $18.50 on Thursday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm’s 50-day simple moving average is $17.32 and its 200-day simple moving average is $17.78. The company has a market cap of $35.44 billion, a price-to-earnings ratio of 24.67 and a beta of 0.59.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date of this dividend is Wednesday, February 11th. Kenvue’s payout ratio is currently 110.67%.

Insiders Place Their Bets

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the company’s stock in a transaction on Friday, December 12th. The shares were bought at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the transaction, the director owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on Kenvue in a report on Friday, October 24th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $15.00 target price (down from $26.00) on shares of Kenvue in a report on Wednesday, October 29th. Finally, Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. Four research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $19.46.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.